Concurrent circulating tumor DNA and tissue-based testing identified more patients eligible for personalized cancer care than either of the tests done alone. There are two popular testing strategies ...
New data from two large studies presented at the 2025 ASCO Gastrointestinal Cancers Symposium (GICS) 2025 provide evidence of the clinical utility of circulating tumor DNA (ctDNA) testing in ...
ctDNA testing effectively stratifies Merkel cell carcinoma patients into high and low recurrence risk categories, influencing surveillance strategies. The study's cohorts revealed significant ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback